ArticleBlood advances2026

Efficacy and safety of BCMA-targeted therapies in relapsed or refractory AL amyloidosis: a descriptive pooled analysis.

Raghad Alqazaqi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.